{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:06:05Z","timestamp":1791889565042,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) groups has identified four molecular prognostic groups of endometrial cancer (EC): POLE-mutated (POLE-mt), mismatch repair-deficient (MMR-d), p53-abnormal (p53-abn), p53-wild-type (p53-wt). These groups might have different pathogenesis and risk factors, and might occur in different phenotypes of patients. However, these data are still lacking.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To provide a clinical characterization of the ProMisE groups of EC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic review and meta-analysis was performed by searching seven electronic databases from their inception to December 2020, for all studies reporting clinical characteristics of EC patients in each ProMisE group. Pooled means of age and BMI and pooled prevalence of FIGO stage I and adjuvant treatment in each ProMisE group were calculated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Six studies with 1, 879 women were included in the systematic review. Pooled means (with standard error) and prevalence values were:<\/jats:p>\n                <jats:p>in the MMR-d group, age\u2009=\u200966.5\u2009\u00b1\u20090.6; BMI\u2009=\u200930.6\u2009\u00b1\u20091.2; stage <jats:italic>I<\/jats:italic>\u2009=\u200972.6%; adjuvant treatment\u2009=\u200947.3%;<\/jats:p>\n                <jats:p>in the POLE-mt group, age\u2009=\u200958.6\u2009\u00b1\u20092.7; BMI\u2009=\u200927.2\u2009\u00b1\u20090.9; stage <jats:italic>I<\/jats:italic>\u2009=\u200993.7%; adjuvant treatment\u2009=\u200953.6%;<\/jats:p>\n                <jats:p>in the p53-wt group, age\u2009=\u200964.2\u2009\u00b1\u20091.9; BMI\u2009=\u200932.3\u2009\u00b1\u20091.4; stage <jats:italic>I<\/jats:italic>\u2009=\u200980.5%; adjuvant treatment\u2009=\u200945.3%;<\/jats:p>\n                <jats:p>in the p53-abn group, age\u2009=\u200971.1\u2009\u00b1\u20090.5; BMI\u2009=\u200929.1\u2009\u00b1\u20090.5; stage <jats:italic>I<\/jats:italic>\u2009=\u200950.8%; adjuvant treatment\u2009=\u200964.4%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The ProMisE groups identify different phenotypes of patients. The POLE-mt group included the youngest women, with the lower BMI and the highest prevalence of stage I. The p53-wt group included patients with the highest BMI. The p53-abn group included the oldest women, with the highest prevalence of adjuvant treatment and the lowest prevalence of stage I. The MMR-d group showed intermediate values among the ProMisE groups for all clinical features.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00404-021-06028-4","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T03:02:17Z","timestamp":1616468537000},"page":"1393-1400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer"],"prefix":"10.1007","volume":"303","author":[{"given":"Antonio","family":"Raffone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4002-1618","authenticated-orcid":false,"given":"Antonio","family":"Travaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olimpia","family":"Gabrielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacarolina","family":"Micheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Zuccal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Bitonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Camastra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Insabato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Zullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"6028_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5\u201329","DOI":"10.3322\/caac.21254"},{"key":"6028_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/bjc.2015.190","volume":"113","author":"A Talhouk","year":"2015","unstructured":"Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N et al (2015) A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 113:299\u2013310","journal-title":"Br J Cancer"},{"key":"6028_CR3","doi-asserted-by":"publisher","unstructured":"Raffone A, Travaglino A, Mascolo M, Carbone L, Guida M, Insabato L, et al (2019) TCGA molecular groups of endometrial cancer: pooled data about prognosis. Gynecol Oncol. [Epub ahead of print]. https:\/\/doi.org\/10.1016\/j.ygyno.2019.08.019","DOI":"10.1016\/j.ygyno.2019.08.019"},{"key":"6028_CR4","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","volume":"37","author":"CB Gilks","year":"2013","unstructured":"Gilks CB, Oliva E, Soslow RA (2013) Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol 37:874\u2013881","journal-title":"Am J Surg Pathol"},{"key":"6028_CR5","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1097\/PAS.0b013e31828c63ed","volume":"37","author":"LN Hoang","year":"2013","unstructured":"Hoang LN, McConechy MK, Kobel M, Han G, Rouzbahman M, Davidson B et al (2013) Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surg Pathol 37:1421\u20131432","journal-title":"Am J Surg Pathol"},{"key":"6028_CR6","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/cncr.30496","volume":"123","author":"A Talhouk","year":"2017","unstructured":"Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J et al (2017) Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123:802\u2013813","journal-title":"Cancer"},{"key":"6028_CR7","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67\u201373","DOI":"10.1038\/nature12113"},{"issue":"29","key":"6028_CR8","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","volume":"1","author":"S Kommoss","year":"2018","unstructured":"Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J et al (2018) Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 1(29):1180\u20131188","journal-title":"Ann Oncol"},{"key":"6028_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ygyno.2019.03.098","volume":"153","author":"H Britton","year":"2019","unstructured":"Britton H, Huang L, Lum A, Leung S, Shum K, Kale M et al (2019) Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol Oncol 153:487\u2013495","journal-title":"Gynecol Oncol"},{"key":"6028_CR10","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41379-018-0080-0","volume":"31","author":"G Kim","year":"2018","unstructured":"Kim G, Kurnit KC, Djordjevic B, Singh C, Munsell MF, Wang WL et al (2018) Nuclear \u03b2-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. Mod Pathol 31:1553\u20131559","journal-title":"Mod Pathol"},{"issue":"8","key":"6028_CR11","doi-asserted-by":"publisher","first-page":"153025","DOI":"10.1016\/j.prp.2020.153025","volume":"216","author":"A Raffone","year":"2020","unstructured":"Raffone A, Travaglino A, Cerbone M et al (2020) Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer. Pathol Res Pract 216(8):153025","journal-title":"Pathol Res Pract"},{"issue":"3","key":"6028_CR12","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s12253-020-00811-5","volume":"26","author":"A Raffone","year":"2020","unstructured":"Raffone A, Travaglino A, Cerbone M et al (2020) Diagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer. Pathol Oncol Res 26(3):1417\u20131427","journal-title":"Pathol Oncol Res"},{"issue":"11","key":"6028_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/apm.12988","volume":"127","author":"A Travaglino","year":"2019","unstructured":"Travaglino A, Raffone A, Saccone G et al (2019) Nuclear expression of \u03b2-catenin in endometrial hyperplasia as marker of premalignancy. APMIS 127(11):699\u2013709","journal-title":"APMIS"},{"key":"6028_CR14","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","volume":"22","author":"E Stelloo","year":"2016","unstructured":"Stelloo E, Nout RA, Osse EM, J\u00fcrgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC et al (2016) Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res 22:4215\u20134224","journal-title":"Clin Cancer Res"},{"key":"6028_CR15","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/modpathol.2015.43","volume":"28","author":"E Stelloo","year":"2015","unstructured":"Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW et al (2015) Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol 28:836\u2013844","journal-title":"Mod Pathol"},{"key":"6028_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/apm.12977","volume":"127","author":"A Raffone","year":"2019","unstructured":"Raffone A, Travaglino A, Saccone G, Cieri M, Mascolo M, Mollo A et al (2019) Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS 127:597\u2013606","journal-title":"APMIS"},{"issue":"1","key":"6028_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ygyno.2020.01.008","volume":"157","author":"A Raffone","year":"2020","unstructured":"Raffone A, Travaglino A, Mascolo M et al (2020) Histopathological characterization of ProMisE molecular groups of endometrial cancer. Gynecol Oncol 157(1):252\u2013259. https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.008","journal-title":"Gynecol Oncol"},{"issue":"6","key":"6028_CR18","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00404-020-05542-1","volume":"301","author":"A Travaglino","year":"2020","unstructured":"Travaglino A, Raffone A, Stradella C et al (2020) Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups. Arch Gynecol Obstet 301(6):1355\u20131363","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"6028_CR19","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s12253-020-00829-9","volume":"26","author":"A Travaglino","year":"2020","unstructured":"Travaglino A, Raffone A, Gencarelli A et al (2020) TCGA classification of endometrial cancer: the place of carcinosarcoma. Pathol Oncol Res 26(4):2067\u20132073","journal-title":"Pathol Oncol Res"},{"issue":"5","key":"6028_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00404-020-05531-4","volume":"301","author":"A Travaglino","year":"2020","unstructured":"Travaglino A, Raffone A, Mollo A et al (2020) TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma. Arch Gynecol Obstet 301(5):1117\u20131125","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"6028_CR21","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s12253-019-00784-0","volume":"26","author":"A Travaglino","year":"2020","unstructured":"Travaglino A, Raffone A, Mascolo M et al (2020) TCGA molecular subgroups in endometrial undifferentiated\/dedifferentiated carcinoma. Pathol Oncol Res 26(3):1411\u20131416","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"6028_CR22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/his.13976","volume":"76","author":"A Travaglino","year":"2020","unstructured":"Travaglino A, Raffone A, Mascolo M et al (2020) Clear cell endometrial carcinoma and the TCGA classification. Histopathology 76(2):336\u2013338","journal-title":"Histopathology"},{"issue":"3","key":"6028_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ygyno.2019.08.001","volume":"154","author":"JN McAlpine","year":"2019","unstructured":"McAlpine JN, Gilks CB (2019) Precision medicine in endometrial cancer. Gynecol Oncol 154(3):451\u2013453","journal-title":"Gynecol Oncol"},{"key":"6028_CR24","first-page":"1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Control Found Appl 4:1","journal-title":"Syst Control Found Appl"},{"key":"6028_CR25","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73:712\u2013716","journal-title":"ANZ J Surg"},{"issue":"3","key":"6028_CR26","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s12253-019-00684-3","volume":"26","author":"A Raffone","year":"2020","unstructured":"Raffone A, Travaglino A, Saccone G et al (2020) Diabetes mellitus is associated with occult cancer in endometrial hyperplasia. Pathol Oncol Res 26(3):1377\u20131384","journal-title":"Pathol Oncol Res"},{"issue":"11","key":"6028_CR27","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1080\/09513590.2019.1624716","volume":"35","author":"A Raffone","year":"2019","unstructured":"Raffone A, Travaglino A, Saccone G et al (2019) Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment. Gynecol Endocrinol 35(11):932\u2013937","journal-title":"Gynecol Endocrinol"},{"key":"6028_CR28","doi-asserted-by":"publisher","unstructured":"Kolehmainen AM, Pasanen AM, Koivisto-Korander RL, B\u00fctzow RC, Loukovaara MJ (2020) Molecular characterization in the prediction of disease extent in endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. (Epub ahead of print) https:\/\/doi.org\/10.1016\/j.ejogrb.2020.10.031","DOI":"10.1016\/j.ejogrb.2020.10.031"},{"issue":"1","key":"6028_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ygyno.2020.01.019","volume":"157","author":"S Timmerman","year":"2020","unstructured":"Timmerman S, Van Rompuy AS, Van Gorp T, Vanden Bempt I, Brems H, Van Nieuwenhuysen E, Han SN, Neven P, Victoor J, Laenen A, Vergote I (2020) Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D. Gynecol Oncol 157(1):245\u2013251","journal-title":"Gynecol Oncol"},{"key":"6028_CR30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ygyno.2019.03.100","volume":"153","author":"MR Moroney","year":"2019","unstructured":"Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA et al (2019) Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers. Gynecol Oncol 153:517\u2013520","journal-title":"Gynecol Oncol"},{"key":"6028_CR31","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","volume":"42","author":"T Bosse","year":"2018","unstructured":"Bosse T, Nout RA, McAlpine JN, McConechy MK, Britton H, Hussein YR et al (2018) Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. Am J Surg Pathol 42:561\u2013568","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"6028_CR32","first-page":"194","volume":"1796","author":"AM Ferreira","year":"2009","unstructured":"Ferreira AM, Westers H, Albergaria A, Seruca R, Hofstra RM (2009) Estrogens, MSI and Lynch syndrome-associated tumors. Biochim Biophys Acta 1796(2):194\u2013200","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"6028_CR33","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/1471-0528.14491","volume":"124","author":"M Zakhour","year":"2017","unstructured":"Zakhour M, Cohen JG, Gibson A et al (2017) Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series. BJOG 124(10):1576\u20131583","journal-title":"BJOG"},{"issue":"1","key":"6028_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","volume":"15","author":"JV Bokhman","year":"1983","unstructured":"Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10\u201317","journal-title":"Gynecol Oncol"},{"key":"6028_CR35","doi-asserted-by":"crossref","unstructured":"Colombo N, Creutzberg C, Amant F, Bosse T, Gonz\u00e1lez-Mart\u00edn A, Ledermann J, et al (2016) ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol 27:16\u201341","DOI":"10.1093\/annonc\/mdv484"},{"key":"6028_CR36","unstructured":"Abu-Rustum NR, Yashar CM, Bean S, et al (2019) NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae)\u2014Uterine neoplasms. Version 3.2019 \u2013 February 11, 2019"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-021-06028-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-021-06028-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-021-06028-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T08:10:47Z","timestamp":1619770247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-021-06028-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["6028"],"URL":"https:\/\/doi.org\/10.1007\/s00404-021-06028-4","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"28 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}